Abnormal liver function before allogeneic BMT has been associated with VOD. Hepatitis G virus/GB virus C (HGV) is a recently discovered virus suggested to be a cause of non-A, non-B, non-C, non-D and non-E hepatitis. The aim of this retrospective study was to analyze the risk for liver complications and time to engraftment in patients infected with HGV. Fifty patients transplanted in 1995 were examined with RT-PCR for HGV on samples collected before, and between 3 and 6 months after BMT. Seven patients had HGV detected before BMT. No patient became infected during or early after the BMT. There were no differences in either preor post-transplant liver function abnormalities, VOD, or time to neutrophil engraftment in patients who did or did not have HGV detected before BMT. We conclude that the importance of HGV infection for the development of post-transplant complications is limited. Keywords: hepatitis G virus; GB virus C; VOD; engraftment Liver function abnormalities are common after allogeneic BMT. Veno-occlusive disease (VOD) of the liver is a severe and frequently fatal complication. Several risk factors have been associated with development of VOD including advanced disease, conditioning regimens containing busulphan and abnormal liver function BMT.
Liver function abnormalities are common after allogeneic BMT. Veno-occlusive disease (VOD) of the liver is a severe and frequently fatal complication. Several risk factors have been associated with development of VOD including advanced disease, conditioning regimens containing busulphan and abnormal liver function BMT. 1, 2 The roles of active hepatitis B and C virus infections before BMT in subsequent liver damage have been controversial with some studies indicating an increased risk of liver damage after BMT and other studies showing no increase in risk. [3] [4] [5] [6] HGV is a recently discovered RNA virus that can be transmitted by blood transfusions. 7 Therefore, many BMT patients can be assumed to be infected at the time of bone marrow transplantation. The aim of this study was to investigate the role of HGV in the development of liver damage in BMT recipients.
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Patients and methods
Fifty consecutive allogeneic BMT recipients were studied. The patients were transplanted between January 1 and December 31 1995. Patient characteristics are shown in Table 1 .
The bone marrow transplant procedure is well described. 8, 9 Forty-five patients were conditioned with cyclophosphamide 60 mg/kg for 2 days followed by single fraction 10 Gy total body irradiation. Patients with unrelated donors received ATG 3-5 mg/kg or OKT-3 (5 mg) for 5 days in addition. Five patients received other conditioning regimens including busulphan and cyclophosphamide (n = 2), cyclophosphamide 50 mg for 4 days combined with ATG 3-5 mg/kg for 4 consecutive days (n = 2), or cyclophosphamide 5 mg/kg for 4 days combined with thoracoabdominal irradiation (n = 1). Prophylaxis against GVHD was with a combination of cyclosporine and methotrexate. [8] [9] [10] VOD was defined according to the criteria described by Jones et al. 11 GVHD was defined according to Thomas et al. 12 Engraftment was defined as the first of 3 consecutive days with an absolute neutrophil count (ANC) 0.5 × 10 9 /l. All patients were studied before and repeatedly after BMT with measurements of s-AST, s-ALT, s-alkaline phosphatase, or s-bilirubin. These tests were performed at least three times a week until engraftment, at least twice weekly until day 100, and thereafter at all routine visits to the clinic. Abnormal liver function tests were defined as more than double the upper normal value of these tests. Severe liver function test abnormalities were defined as more than 10 times the upper normal value of either of these four tests.
Virology
All patients were studied for HBsAg, and HCV RNA as part of a routine evaluation before, and for follow-up after BMT. Samples obtained for these routine investigations were retrospectively analyzed for HGV RNA by reversetranscriptase polymerase chain reaction (RT-PCR). Total RNA was extracted from 100 l of serum by guanidinium extraction as described previously. 13 cDNA synthesis was initiated by using reverse-transcriptase (Boehringer, Mannheim, Germany). HGV DNA was amplified by PCR of the 5′ noncoding region by using outer primer pair sense HGV-1X (nucleotides 205-222) and antisense HGV-2X (nucleotides 533-516) as described, 14 nested with inner primer pair, previously described. 13, 15 The nested PCR amplifies a product of approximately 245 bp.
All stem cell donors were studied as a part of the routine pre-transplant evaluation for HBsAg and either HCV RNA or HCV antibodies by RIBA. Donor sera (n = 5) were analyzed for HGV RNA with RT PCR when available.
Results

HGV RNA detection before and after BMT
Seven of 50 patients (14%) were HGV PCR positive before BMT. One patient had HBsAg detected while no patient was positive for HCV RNA before BMT. There were no differences in the frequencies of abnormal liver function tests in patients who were positive (2 of 7; 28%) or negative (12 of 43; 28%) for HGV DNA before BMT. All patients who were HGV positive had received blood transfusions, while 15 of 43 patients without HGV had not received any transfusion. No donor tested had either HGV or HCV DNA before BMT.
Forty-eight patients were retested after BMT. Two patients died before engraftment and had no follow-up samples available for analysis. Six of the 48 patients studied were HGV PCR-positive after BMT. All these patients were already HGV RNA-positive before BMT. No patient who was HGV PCR negative became PCR-positive after the BMT.
Liver function tests before and after BMT
Two of seven (28%) patients with HGV had abnormal liver function tests before BMT compared to 12 of 43 (28%) patients who did not have HGV detected (P = NS; Fisher's exact test). All seven patients (100%) with HGV had at least one abnormal liver function test after BMT compared to 39 of 43 (91%) of patients without detectable HGV (P = NS; Fisher's exact test). Three of seven (43%) HGVpositive patients had severe liver function test abnormalities compared to 11 of 43 (26%) patients without HGV (P = NS; Fisher's exact test).
Engraftment, VOD and GVHD
There was no difference in the time to engraftment between patients with or without HGV before BMT (Figure 1 ; logrank test). Two (28%) patients with HGV developed VOD compared to six (14%) patients without HGV (P = NS; Fisher's exact test). None of seven HGV-positive patients developed acute GVHD of grade II compared to eight of 43 patients without HGV infection (P = NS; Fisher's exact test).
Discussion
HGV is a recently discovered virus that can be parenterally transmitted. 16 The prevalence of HGV in voluntary blood donors in the USA is reported to be 1-2%. Thus, the likelihood is high that multitransfused patients such as allogeneic BMT recipients are infected with HGV. This is supported by our study since all patients who tested positive for HGV before BMT had been transfused while none of the nontransfused patients had HGV RNA detected. The clinical significance of HGV in different patient populations has been studied, and generally speaking this is low. Recently, Rodriguez-Inigo et al 17 presented data on Spanish allogeneic BMT recipients showing a very high incidence of HGV infection (42%) but no correlation with liver disease or engraftment kinetics. They also showed that 19% of patients contracted HGV at or early after BMT. Finally, almost half of their patients infected with HGV were also infected with HCV.
Our patient group differs from the patient group described by Rodriguez-Inigo et al in that the frequency of HGV was only 14% and no patient contracted HGV during the transplant procedure, presumably reflecting the prevalence of HGV infection in the blood donor pool. We could only test a minority of the marrow donors but this is probably of little importance since no patient contracted HGV infection after the transplant. Furthermore, none of our patients had HCV infection and therefore the possible confounding effects of HCV on both the HGV infected and uninfected patients can be disregarded. Despite these differences in the patient cohorts, our results are very similar to the previously published series, showing no difference in the risk for either mild or severe liver disease after BMT. Each of the two studies are small with a low number of patients infected with HGV. However, the results of these studies taken together strongly argue against a significant impact of HGV on liver function after allogeneic BMT. This is in agreement with other patient categories suggesting that severe liver disease caused by HGV is uncommon. 16, 18 There is an ongoing discussion regarding the role of HGV in the etiology of aplastic anemia occurring with or without associated hepatitis. [19] [20] [21] We detect no difference in the kinetics of marrow engraftment in HGV infected or uninfected patients. Thus, the results of our study together with the study of Rodriguez-Inigo et al argue against a direct effect of HGV on hematopoietic progenitors. However, the possibility of an immune-mediated effect depressing hematopoiesis can not be ruled out.
